

Peter B Gilbert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3670716/publications.pdf>

Version: 2024-02-01

160
papers

23,722
citations

43973

48
h-index

9073

144
g-index

173
all docs

173
docs citations

173
times ranked

25366
citing authors

#	ARTICLE	IF	CITATIONS
1	A General Framework for Inference on Algorithm-Agnostic Variable Importance. Journal of the American Statistical Association, 2023, 118, 1645-1658.	1.8	12
2	Analysis of Neutralizing Antibodies as a Correlate of Instantaneous Risk of Hospitalized Dengue in Placebo Recipients of Dengue Vaccine Efficacy Trials. Journal of Infectious Diseases, 2022, 225, 332-340.	1.9	1
3	Evaluating Vaccine Efficacy Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Clinical Infectious Diseases, 2022, 74, 544-552.	2.9	9
4	Associations of human leukocyte antigen with neutralizing antibody titers in a tetravalent dengue vaccine phase 2 efficacy trial in Thailand. Human Immunology, 2022, 83, 53-60.	1.2	3
5	Innovative vaccine approaches—a Keystone Symposia report. Annals of the New York Academy of Sciences, 2022, 1511, 59-86.	1.8	5
6	Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science, 2022, 375, 43-50.	6.0	788
7	Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention. PLoS Computational Biology, 2022, 18, e1010003.	1.5	8
8	Tracking SARS-CoV-2 Spike Protein Mutations in the United States (January 2020—March 2021) Using a Statistical Learning Strategy. Viruses, 2022, 14, 9.	1.5	10
9	Analysis of the HIV Vaccine Trials Network 702 Phase 2b—3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk. Journal of Infectious Diseases, 2022, 226, 246-257.	1.9	11
10	Efficient nonparametric inference on the effects of stochastic interventions under two-phase sampling, with applications to vaccine efficacy trials. Biometrics, 2021, 77, 1241-1253.	0.8	15
11	Nonparametric variable importance assessment using machine learning techniques. Biometrics, 2021, 77, 9-22.	0.8	33
12	Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials. Annals of Internal Medicine, 2021, 174, 221-228.	2.0	86
13	Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. New England Journal of Medicine, 2021, 384, 403-416.	13.9	7,910
14	Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials. EBioMedicine, 2021, 64, 103203.	2.7	14
15	Sieve analysis to understand how SARS-CoV-2 diversity can impact vaccine protection. PLoS Pathogens, 2021, 17, e1009406.	2.1	16
16	Evaluating the Long-term Efficacy of Coronavirus Disease 2019 (COVID-19) Vaccines. Clinical Infectious Diseases, 2021, 73, 1927-1939.	2.9	19
17	Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120—MF59 in Adults. New England Journal of Medicine, 2021, 384, 1089-1100.	13.9	144
18	Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. New England Journal of Medicine, 2021, 384, 1003-1014.	13.9	270

#	ARTICLE	IF	CITATIONS
19	Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk. <i>PLoS Pathogens</i> , 2021, 17, e1009363.	2.1	19
20	Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans. <i>Npj Vaccines</i> , 2021, 6, 56.	2.9	7
21	Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, 671-679.	0.9	16
22	Super LeArner Prediction of NAb Panels (SLAPNAP): a containerized tool for predicting combination monoclonal broadly neutralizing antibody sensitivity. <i>Bioinformatics</i> , 2021, 37, 4187-4192.	1.8	9
23	RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infection. <i>Virus Evolution</i> , 2021, 7, veab057.	2.2	2
24	Evidence for antibody as a protective correlate for COVID-19 vaccines. <i>Vaccine</i> , 2021, 39, 4423-4428.	1.7	766
25	A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated. <i>Annals of Internal Medicine</i> , 2021, 174, 1118-1125.	2.0	15
26	Mathematical Modeling of Vaccines That Prevent SARS-CoV-2 Transmission. <i>Viruses</i> , 2021, 13, 1921.	1.5	10
27	A government-led effort to identify correlates of protection for COVID-19 vaccines. <i>Nature Medicine</i> , 2021, 27, 1493-1494.	15.2	26
28	Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. <i>New England Journal of Medicine</i> , 2021, 385, 1774-1785.	13.9	402
29	Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. <i>Science</i> , 2021, , eab3435.	6.0	145
30	Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation. <i>Scientific Reports</i> , 2021, 11, 23921.	1.6	44
31	Methods for comparing durability of immune responses between vaccine regimens in early-phase trials. <i>Statistical Methods in Medical Research</i> , 2020, 29, 78-93.	0.7	1
32	Inference on treatment effect modification by biomarker response in a three-phase sampling design. <i>Biostatistics</i> , 2020, 21, 545-560.	0.9	7
33	Prospects for a safe COVID-19 vaccine. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	204
34	Evaluating the Efficacy of Coronavirus Disease 2019 Vaccines. <i>Clinical Infectious Diseases</i> , 2020, 73, 1540-1544.	2.9	15
35	Causal isotonic regression. <i>Journal of the Royal Statistical Society Series B: Statistical Methodology</i> , 2020, 82, 719-747.	1.1	5
36	Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America. <i>PLoS ONE</i> , 2020, 15, e0234236.	1.1	9

#	ARTICLE	IF	CITATIONS
37	Assessment of the long-term efficacy of a dengue vaccine against symptomatic, virologically-confirmed dengue disease by baseline dengue serostatus. <i>Vaccine</i> , 2020, 38, 3531-3536.	1.7	12
38	Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. <i>PLoS Medicine</i> , 2020, 17, e1003038.	3.9	27
39	HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens. <i>Scientific Reports</i> , 2020, 10, 2093.	1.6	17
40	A regularized estimation approach for case-cohort periodic follow-up studies with an application to HIV vaccine trials. <i>Biometrical Journal</i> , 2020, 62, 1176-1191.	0.6	6
41	Brief Report: Prediction of Serum HIV-1 Neutralization Titers After Passive Administration of VRC01. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, 434-439.	0.9	3
42	Generating Survival Times Using Cox Proportional Hazards Models with Cyclic and Piecewise Time-Varying Covariates. <i>Statistics in Biosciences</i> , 2020, 12, 324-339.	0.6	3
43	Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection. <i>MSphere</i> , 2020, 5, .	1.3	3
44	Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials. <i>PLoS Medicine</i> , 2020, 17, e1003117.	3.9	8
45	Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans. <i>PLoS ONE</i> , 2020, 15, e0226803.	1.1	16
46	RV144 HIV-1 vaccination impacts post-infection antibody responses. <i>PLoS Pathogens</i> , 2020, 16, e1009101.	2.1	13
47	Assessing trends in vaccine efficacy by pathogen genetic distance. <i>Journal De La SFdS</i> , 2020, 161, 164-175.	0.5	1
48	Title is missing!. , 2020, 16, e1007626.		0
49	Title is missing!. , 2020, 16, e1007626.		0
50	Title is missing!. , 2020, 16, e1007626.		0
51	Title is missing!. , 2020, 16, e1007626.		0
52	Title is missing!. , 2020, 15, e0234236.		0
53	Title is missing!. , 2020, 15, e0234236.		0
54	Title is missing!. , 2020, 15, e0234236.		0

#	ARTICLE	IF	CITATIONS
55	Title is missing!. , 2020, 15, e0234236.		0
56	Combining Viral Genetics and Statistical Modeling to Improve HIV-1 Time-of-Infection Estimation towards Enhanced Vaccine Efficacy Assessment. <i>Viruses</i> , 2019, 11, 607.	1.5	12
57	Assessing pharmacokinetic marker correlates of outcome, with application to antibody prevention efficacy trials. <i>Statistics in Medicine</i> , 2019, 38, 4503-4518.	0.8	9
58	Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial. <i>Journal of Virology</i> , 2019, 93, .	1.5	26
59	A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge. <i>Cell Host and Microbe</i> , 2019, 26, 336-346.e3.	5.1	88
60	Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	46
61	Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial. <i>Lancet HIV</i> ,the, 2019, 6, e737-e749.	2.1	43
62	HAI and NAI titer correlates of inactivated and live attenuated influenza vaccine efficacy. <i>BMC Infectious Diseases</i> , 2019, 19, 453.	1.3	23
63	Revisiting the Correlate of Reduced HIV Infection Risk in the Rv144 Vaccine Trial. <i>Journal of Virology</i> , 2019, 93, .	1.5	7
64	Taking stock of the present and looking ahead: envisioning challenges in the design of future HIV prevention efficacy trials. <i>Lancet HIV</i> ,the, 2019, 6, e475-e482.	2.1	19
65	Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features. <i>PLoS Computational Biology</i> , 2019, 15, e1006952.	1.5	25
66	Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine. <i>Nature Communications</i> , 2019, 10, 863.	5.8	27
67	Estimating and Testing Vaccine Sieve Effects Using Machine Learning. <i>Journal of the American Statistical Association</i> , 2019, 114, 1038-1049.	1.8	15
68	Antigenic competition in CD4 ⁺ T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	18
69	Ongoing Vaccine and Monoclonal Antibody HIV Prevention Efficacy Trials and Considerations for Sequel Efficacy Trial Designs. <i>Statistical Communications in Infectious Diseases</i> , 2019, 11, .	0.2	2
70	Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector Cells. <i>Frontiers in Immunology</i> , 2019, 10, 2741.	2.2	25
71	Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk. <i>Journal of Clinical Investigation</i> , 2019, 129, 4838-4849.	3.9	95
72	Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019, 101, 164-179.	0.6	9

#	ARTICLE	IF	CITATIONS
73	Projected effectiveness and added value of HIV vaccination campaigns in South Africa: A modeling study. <i>Scientific Reports</i> , 2018, 8, 6066.	1.6	17
74	A joint model for mixed and truncated longitudinal data and survival data, with application to HIV vaccine studies. <i>Biostatistics</i> , 2018, 19, 374-390.	0.9	8
75	Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial. <i>Journal of Infectious Diseases</i> , 2018, 217, 1280-1288.	1.9	32
76	Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America. <i>Journal of Infectious Diseases</i> , 2018, 217, 742-753.	1.9	80
77	Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 2116-2127.	1.4	17
78	Estimation of the Optimal Surrogate Based on a Randomized Trial. <i>Biometrics</i> , 2018, 74, 1271-1281.	0.8	24
79	Improved estimation of the cumulative incidence of rare outcomes. <i>Statistics in Medicine</i> , 2018, 37, 280-293.	0.8	20
80	Statistical Learning Methods to Determine Immune Correlates of Herpes Zoster in Vaccine Efficacy Trials. <i>Journal of Infectious Diseases</i> , 2018, 218, S99-S101.	1.9	10
81	Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. <i>Lancet HIV</i> , 2018, 5, e366-e378.	2.1	86
82	Weighing the Evidence of Efficacy of Oral PrEP for HIV Prevention in Women in Southern Africa. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 645-656.	0.5	23
83	Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E8378-E8387.	3.3	57
84	Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy. <i>New England Journal of Medicine</i> , 2018, 379, 327-340.	13.9	557
85	Predictors of durable immune responses six months after the last vaccination in preventive HIV vaccine trials. <i>Vaccine</i> , 2017, 35, 1184-1193.	1.7	9
86	Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults. <i>MAbs</i> , 2017, 9, 792-800.	2.6	43
87	Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial. <i>Journal of Infectious Diseases</i> , 2017, 215, 1376-1385.	1.9	59
88	SieveSifter: a web-based tool for visualizing the sieve analyses of HIV-1 vaccine efficacy trials. <i>Bioinformatics</i> , 2017, 33, 2386-2388.	1.8	4
89	chngpt: threshold regression model estimation and inference. <i>BMC Bioinformatics</i> , 2017, 18, 454.	1.2	123
90	DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8 ⁺ T-Cell Responses by Interleukin-12 Plasmid DNA. <i>Vaccine Journal</i> , 2017, 24, .	3.2	33

#	ARTICLE	IF	CITATIONS
91	Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials. <i>Statistical Communications in Infectious Diseases</i> , 2017, 9, .	0.2	62
92	Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women. <i>PLoS ONE</i> , 2017, 12, e0176428.	1.1	12
93	Peptide Targeted by Human Antibodies Associated with HIV Vaccine-Associated Protection Assumes a Dynamic α -Helical Structure. <i>PLoS ONE</i> , 2017, 12, e0170530.	1.1	13
94	Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults. <i>PLoS ONE</i> , 2017, 12, e0179597.	1.1	29
95	V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144. <i>PLoS ONE</i> , 2017, 12, e0180720.	1.1	55
96	Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120. <i>PLoS ONE</i> , 2017, 12, e0185959.	1.1	27
97	Power/sample size calculations for assessing correlates of risk in clinical efficacy trials. <i>Statistics in Medicine</i> , 2016, 35, 3745-3759.	0.8	8
98	Predicting Overall Vaccine Efficacy in a New Setting by Re-calibrating Baseline Covariate and Intermediate Response Endpoint Effect Modifiers of Type-Specific Vaccine Efficacy. <i>Epidemiologic Methods</i> , 2016, 5, 93-112.	0.8	13
99	Search continues for a CMV vaccine for transplant recipients. <i>Lancet Haematology</i> , 2016, 3, e58-e59.	2.2	3
100	Mark-specific hazard ratio model with missing multivariate marks. <i>Lifetime Data Analysis</i> , 2016, 22, 606-625.	0.4	11
101	Modeling HIV vaccine trials of the future. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 620-627.	1.5	5
102	Selection of HIV vaccine candidates for concurrent testing in an efficacy trial. <i>Current Opinion in Virology</i> , 2016, 17, 57-65.	2.6	14
103	Pooled-Peptide Epitope Mapping Strategies Are Efficient and Highly Sensitive: An Evaluation of Methods for Identifying Human T Cell Epitope Specificities in Large-Scale HIV Vaccine Efficacy Trials. <i>PLoS ONE</i> , 2016, 11, e0147812.	1.1	42
104	FCGR2C Polymorphisms Associated with HIV-1 Vaccine Protection Are Linked to Altered Gene Expression of Fc γ 3 Receptors in Human B Cells. <i>PLoS ONE</i> , 2016, 11, e0152425.	1.1	11
105	Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants. <i>PLoS ONE</i> , 2016, 11, e0161753.	1.1	16
106	Surrogate Endpoint Evaluation: Principal Stratification Criteria and the Prentice Definition. <i>Journal of Causal Inference</i> , 2015, 3, 157-175.	0.5	13
107	Calibration weighted estimation of semiparametric transformation models for two-phase sampling. <i>Statistics in Medicine</i> , 2015, 34, 1695-1707.	0.8	4
108	Inferences on relative failure rates in stratified mark-specific proportional hazards models with missing marks, with application to human immunodeficiency virus vaccine efficacy trials. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2015, 64, 49-73.	0.5	15

#	ARTICLE	IF	CITATIONS
109	Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals. <i>Journal of AIDS & Clinical Research</i> , 2015, 06, .	0.5	17
110	Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials. <i>PLoS ONE</i> , 2015, 10, e0136626.	1.1	23
111	COMPASS identifies T-cell subsets correlated with clinical outcomes. <i>Nature Biotechnology</i> , 2015, 33, 610-616.	9.4	232
112	Reply to Dunning. <i>Journal of Infectious Diseases</i> , 2015, 212, 1521.2-1523.	1.9	0
113	Use of placebos in Phase 1 preventive HIV vaccine clinical trials. <i>Vaccine</i> , 2015, 33, 749-752.	1.7	2
114	Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial. <i>PLoS Computational Biology</i> , 2015, 11, e1003973.	1.5	51
115	HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition. <i>Science Translational Medicine</i> , 2015, 7, 296ra112.	5.8	47
116	Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine. <i>New England Journal of Medicine</i> , 2015, 373, 2025-2037.	13.9	332
117	Immune correlates of vaccine protection against HIV-1 acquisition. <i>Science Translational Medicine</i> , 2015, 7, 310rv7.	5.8	179
118	HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders. <i>Nature Medicine</i> , 2015, 21, 1139-1141.	15.2	50
119	Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men. <i>PLoS ONE</i> , 2015, 10, e0137666.	1.1	30
120	Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial Reveals an Association of Nonspecific Interferon- β Secretion with Increased HIV-1 Infection Risk: A Cohort-Based Modeling Study. <i>PLoS ONE</i> , 2014, 9, e108631.	1.1	23
121	Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses. <i>EBioMedicine</i> , 2014, 1, 37-45.	2.7	55
122	Fold Rise in Antibody Titers by Measured by Glycoprotein-Based Enzyme-Linked Immunosorbent Assay Is an Excellent Correlate of Protection for a Herpes Zoster Vaccine, Demonstrated via the Vaccine Efficacy Curve. <i>Journal of Infectious Diseases</i> , 2014, 210, 1573-1581.	1.9	84
123	Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination. <i>Science Translational Medicine</i> , 2014, 6, 228ra39.	5.8	412
124	Phase I/II Randomized Trial of Safety and Immunogenicity of LIPO-5 Alone, ALVAC-HIV (vCP1452) Alone, and ALVAC-HIV (vCP1452) Prime/LIPO-5 Boost in Healthy, HIV-1-Uninfected Adult Participants. <i>Vaccine Journal</i> , 2014, 21, 1589-1599.	3.2	10
125	Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 388-396.	4.6	108
126	Optimal auxiliary-covariate-based two-phase sampling design for semiparametric efficient estimation of a mean or mean difference, with application to clinical trials. <i>Statistics in Medicine</i> , 2014, 33, 901-917.	0.8	9

#	ARTICLE	IF	CITATIONS
127	Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A25-A26.	0.5	0
128	Analysis of HLA A*02 Association with Vaccine Efficacy in the RV144 HIV-1 Vaccine Trial. <i>Journal of Virology</i> , 2014, 88, 8242-8255.	1.5	55
129	FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. <i>Journal of Clinical Investigation</i> , 2014, 124, 3879-3890.	3.9	99
130	Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection. <i>PLoS ONE</i> , 2014, 9, e87572.	1.1	248
131	Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine. <i>New England Journal of Medicine</i> , 2013, 369, 2083-2092.	13.9	518
132	HIV-1 Vaccine-Induced T-Cell Responses Cluster in Epitope Hotspots that Differ from Those Induced in Natural Infection with HIV-1. <i>PLoS Pathogens</i> , 2013, 9, e1003404.	2.1	39
133	Vaccine-Induced Gag-Specific T Cells Are Associated With Reduced Viremia After HIV-1 Infection. <i>Journal of Infectious Diseases</i> , 2013, 208, 1231-1239.	1.9	73
134	Sensitivity Analysis of Per-Protocol Time-to-Event Treatment Efficacy in Randomized Clinical Trials. <i>Journal of the American Statistical Association</i> , 2013, 108, 789-800.	1.8	6
135	Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial. <i>PLoS ONE</i> , 2013, 8, e75665.	1.1	214
136	Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials. <i>Journal of Infectious Diseases</i> , 2012, 206, 431-441.	1.9	273
137	Extended Follow-up Confirms Early Vaccine-Enhanced Risk of HIV Acquisition and Demonstrates Waning Effect Over Time Among Participants in a Randomized Trial of Recombinant Adenovirus HIV Vaccine (Step Study). <i>Journal of Infectious Diseases</i> , 2012, 206, 258-266.	1.9	202
138	Nomenclature for Immune Correlates of Protection After Vaccination. <i>Clinical Infectious Diseases</i> , 2012, 54, 1615-1617.	2.9	297
139	The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1444-1457.	0.5	191
140	Rejoinder to "A Note on Two-sample Tests for Comparing Intra-individual Genetic Sequence Diversity Between Populations". <i>Biometrics</i> , 2012, 68, 1326-1326.	0.8	0
141	Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 531-537.	4.6	201
142	Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. <i>Nature</i> , 2012, 490, 417-420.	13.7	405
143	Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial. <i>New England Journal of Medicine</i> , 2012, 366, 1275-1286.	13.9	1,699
144	Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells. <i>Journal of Immunological Methods</i> , 2012, 375, 57-67.	0.6	69

#	ARTICLE	IF	CITATIONS
145	Commentary on "Principal Stratification – a Goal or a Tool?" by Judea Pearl. International Journal of Biostatistics, 2011, 7, 1-15.	0.4	22
146	Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nature Medicine, 2011, 17, 366-371.	15.2	220
147	Statistical Interpretation of the RV144 HIV Vaccine Efficacy Trial in Thailand: A Case Study for Statistical Issues in Efficacy Trials. Journal of Infectious Diseases, 2011, 203, 969-975.	1.9	91
148	Some design issues in phase 2B vs phase 3 prevention trials for testing efficacy of products or concepts. Statistics in Medicine, 2010, 29, 1061-1071.	0.8	19
149	Magnitude and Breadth of a Nonprotective Neutralizing Antibody Response in an Efficacy Trial of a Candidate HIV gp120 Vaccine. Journal of Infectious Diseases, 2010, 202, 595-605.	1.9	118
150	Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies. Journal of Virology, 2010, 84, 1439-1452.	1.5	589
151	Simultaneous Evaluation of the Magnitude and Breadth of a Left- and Right-Censored Multivariate Response, With Application to HIV Vaccine Development. Statistics in Biopharmaceutical Research, 2009, 1, 81-91.	0.6	37
152	Genome Scanning Tests for Comparing Amino Acid Sequences Between Groups. Biometrics, 2008, 64, 198-207.	0.8	18
153	Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet, The, 2008, 372, 1881-1893.	6.3	1,560
154	A Framework for Assessing Immunological Correlates of Protection in Vaccine Trials. Journal of Infectious Diseases, 2007, 196, 1304-1312.	1.9	195
155	Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. Vaccine, 2006, 24, 6893-6904.	1.7	93
156	Covariability of Selected Amino Acid Positions for HIV Type 1 Subtypes C and B. AIDS Research and Human Retroviruses, 2005, 21, 1016-1030.	0.5	36
157	Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies. Journal of Virology, 2005, 79, 10108-10125.	1.5	1,025
158	Simultaneous Inferences on the Contrast of Two Hazard Functions with Censored Observations. Biometrics, 2002, 58, 773-780.	0.8	39
159	Sieve analysis. Journal of Clinical Epidemiology, 2001, 54, 68-85.	2.4	54
160	Estimation of conditional cumulative incidence functions under generalized semiparametric regression models with missing covariates, with application to analysis of biomarker correlates in vaccine trials. Canadian Journal of Statistics, 0, , .	0.6	0